Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.87 |
| ▸ | MET | P08581 | 9/20 | 0.87 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.87 |
| ▸ | TEK | Q02763 | 2/20 | 0.87 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.87 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 3/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | HCK | P08631 | 2/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | ABL2 | P42684 | 2/20 | 0.52 |
| ▸ | FRK | P42685 | 2/20 | 0.52 |
| ▸ | MST1R | Q04912 | 2/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.52 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altiratinib SCHEMBL139906 | 0.93 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| Altiratinib SCHEMBL30337737 | 0.93 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| Altiratinib SCHEMBL29358783 | 0.93 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| Altiratinib SCHEMBL30128694 | 0.93 | KDR (1.00) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL142079 | 0.92 | KDR (0.93) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL138396 | 0.87 | MET (0.82) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL2592755 | 0.86 | KDR (0.81) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL143639 | 0.85 | MET (0.78) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL143640 | 0.85 | MET (0.78) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL143778 | 0.85 | MET (0.78) | KDRMETNTRK1TEKNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563362-B1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-03-12 | — | — | EP | claimed |
| US-8637672-B2 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-01-28 | — | — | US | claimed |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-12-20 | — | — | US | claimed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | claimed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | claimed |
| US-20150218130-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| US-20140194405-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2563362-B1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8637672-B2 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHAMACEUTICALS, LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194405-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDR 3640/4885MET 2169/4885NTRK1 3749/4885 |
| US-20120252849-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDR 3640/4885MET 2169/4885NTRK1 3749/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | KDR 152/4885MET 1610/4885NTRK1 3618/4885 |
| US-20120322834-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDR 3640/4885MET 2169/4885NTRK1 3749/4885 |
| US-20120058985-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDR 3640/4885MET 2169/4885NTRK1 3749/4885 |
| US-20150218130-A1 | CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KDR 3640/4885MET 2169/4885NTRK1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.